GT Biopharma's market cap is currently $3.84M. The company's EPS TTM is $-0.55; its P/E ratio is ―; GT Biopharma is scheduled to report earnings on August 14, 2025, and the estimated EPS forecast is $-0.38. See an overview of income statement, balance sheet, and cash flow financials.
